Clinical research
MorphoSys AG andI-Mab Biopharma announced that the first patient has been dosed in a phase 2 clinical study in Taiwan to evaluate MorphoSys’s investigational human CD38 antibody TJ202/MOR202 in patients with relapsed or refractory multiple myeloma.
Biotech and pharma companies from across Europe and Asia provide updates on pipeline and business activities.
The trial, which paired a checkpoint inhibitor and PARP inhibitor, was not likely to hit endpoints. It was the second ovarian cancer trial failure for the two companies in six months.
Only a few months after GlaxoSmithKline acquired Waltham, Mass.-based Tesaro, Tesaro released promising data from its Phase I/II GARNET study of dostarlimab in endometrial cancer.
The approval of Zulresso marks the first and only treatment for postpartum depression (PPD) approved by the U.S. Food and Drug Administration.
March is National Kidney Month, with March 14 designated as World Kidney Day. The kidneys are called the body’s chemical factories. Their job is to filter waste and perform specific important jobs like controlling red blood cell production and blood pressure.
The company announced positive topline results from its Phase III EMPOWUR trial of viregron in patients with overactive bladder.
In a Phase III trial, a higher proportion of deaths was observed in the venetoclax arm compared to the control arm of the trial.
Esperion, based in Ann Arbor, Mich., announced results from its Phase III Study 2 of bempedoic acid at the American College of Cardiology (ACC) annual meeting.
UK-based Allergy Therapeutics markets three allergy “jabs” for tree pollen, dust mites, and grass pollen. Later this year it is planning results from a Phase I trial of a dust mite vaccine. But the company’s results from its trial for a birch pollen vaccine are a bit puzzling—the vaccine flunked the trial, but appeared to show positive results.
PRESS RELEASES